These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34047507)

  • 1. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
    Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
    Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
    Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
    Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.
    Wang Y; Yang D; Xu L; Yang S; Wang W; Zheng C; Zhang X; Wu B; Yin H; Yang Z; Xu H
    Abdom Radiol (NY); 2024 Sep; 49(9):3078-3087. PubMed ID: 38642094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
    Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
    Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtraction Images From Portal Venous Phase Gadoxetic Acid-Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018.
    Chung JW; Yu JS; Choi JM; Cho ES; Kim JH; Chung JJ
    AJR Am J Roentgenol; 2020 Jan; 214(1):72-80. PubMed ID: 31573851
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
    Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
    Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
    Kim SS; Lee S; Kim MJ
    Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.
    Choi SH; Kim SY; Lee SS; Shim JH; Byun JH; Baek S; Lee MG
    AJR Am J Roentgenol; 2017 Sep; 209(3):584-591. PubMed ID: 28609188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
    Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: Diagnostic performance of category-adjusted LR-5 using modified criteria.
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    PLoS One; 2020; 15(11):e0242344. PubMed ID: 33186378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.